COVID-19 Impact on Coloplast A/S’s Revenue and Operations (Medical Devices)


Summary

Coloplast A/S (Coloplast), manufactures and sells products and offers services for ostomy care, urology care, continence care, and skin and wound care, headquartered in Denmark with global manufacturing and sales reach. Coloplast A/S (Coloplast) manufactures and sells products and offers services for ostomy care, urology care, continence care, and skin and wound care. Its major products include ostomy bags; urisheaths; urine bags; catheters; anal irrigation systems; vaginal sling products; advanced foam dressings and hydrocolloid dressings for infected, non-infected and painful wounds; cleansers; moisturizers; skin protectants; anti-fungals; and hand cleansers. It also offers a wide range of disposable products to support endourological and percutaneous procedures, prostate disorders, laparoscopic procedures, and testicular prosthesis. The report, COVID-19 Impact on Coloplast A/S’s Revenue and Operations (Medical Devices) presents a deep dive analysis into how Coloplast A/S is placed to respond to the COVID-19 crisis, by examining its sector performance and competitiveness.

Deep dive analysis into how Coloplast A/S is placed to respond to the COVID-19 crisis, by examining its sector performance and competitiveness.


Key Highlights

  • The outbreak of the disease in recent days has affected a significant proportion of Coloplast’s.
  • The strong impact in Europe in particular and the rapid growth of COVID-19 cases in the US mean that the overall revenue outlook has dramatically deteriorated in the past week.




Scope

The report provides a comprehensive analysis of the impact of COVID-19 on Coloplast A/S -

  • It provides insights on Coloplast A/S’s exposure to the regions and businesses impacted by the COVID-19 outbreak.
  • It offers an overview of the company’s revenue impact by region and market for 2020 due to the COVID-19 outbreak.




Reasons To Buy

  • An overview of how Coloplast A/S will be affected by the COVID-19 pandemic.